Triple negative breast cancer: BRCA1/BRCA2 germline mutation status predicts response to polychemotherapy

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

IMPORTANCE The GeparSixto trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting of anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Whether BRCA1 and BRCA2 ger...